focus -WSS

focus

author：focus 2025-09-30 00:49:06 - browse：46393

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Cardiologists urge adding sexual orientation, gender identity to health records

hotspot

WSS

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Medical device trials still don't enroll enough women, study finds

STAT Virtual Event: ASCO Recap, Live!

Mass General, Mayo Clinic look to monetize custom

Coercive sterilizations revealed by STAT prompt outrage

knowledge

focus

hotspot

In age of alternative facts, a scholarly course on calling out crap

Report captures long Covid’s disabling effects and policy challenges

Apple is now the first public company to be valued at $3 trillion

Cheap, fast test for Zika and dengue could cost just $1

Walensky prepares to leave CDC — and Congress — behind

The system is set up to fail children with medical complexity

Supreme Court strikes down use of affirmative action

NIH tests clinical research in primary care with $30 million program

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Teladoc has a new CEO, but challenges remain the same

entertainment

The inclusion problem at the heart of rehabilitation research

My daughter's legacy lives on through her writing, phage therapy

There's an unseen cost to disruptive road

The system is set up to fail children with medical complexity

High breast density mammograms need follow

HPV vaccine, cervical cancer study delivers historic results

hotspot

hotspot

explore

leisure time